{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T14:18:23Z","timestamp":1780582703199,"version":"3.54.1"},"reference-count":25,"publisher":"Public Library of Science (PLoS)","issue":"10","license":[{"start":{"date-parts":[[2015,10,8]],"date-time":"2015-10-08T00:00:00Z","timestamp":1444262400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0139717","type":"journal-article","created":{"date-parts":[[2015,10,8]],"date-time":"2015-10-08T18:14:07Z","timestamp":1444328047000},"page":"e0139717","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":25,"title":["Adjunctive Aripiprazole Treatment for Risperidone-Induced Hyperprolactinemia: An 8-Week Randomized, Open-Label, Comparative Clinical Trial"],"prefix":"10.1371","volume":"10","clinical-trial-number":[{"clinical-trial-number":"chictr-ior-15006278","registry":"10.18810\/chictr"}],"author":[{"given":"Jingyuan","family":"Zhao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xueqin","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoqing","family":"Ai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaojing","family":"Gu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangbiao","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lijuan","family":"Pang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minli","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuang","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luxian","family":"Lv","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2015,10,8]]},"reference":[{"issue":"Suppl 2","key":"ref1","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/S0306-4530(02)00127-0","article-title":"Prevalence of hyperprolactinemia in schizophrenic patients treated with conventional antipsychotic medications or risperidone","volume":"28","author":"BJ Kinon","year":"2003","journal-title":"Psychoneuroendocrinology"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1016\/S0022-5347(17)38964-4","article-title":"Hyperprolactinemia and impotence: why, when and how to investigate","volume":"142","author":"MP Leonard","year":"1989","journal-title":"The Journal of urology"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1017\/S1461145706007115","article-title":"Amisulpride-induced hyperprolactinaemia is not reversed by addition of aripiprazole","volume":"10","author":"M Paulzen","year":"2007","journal-title":"The international journal of neuropsychopharmacology \/ official scientific journal of the Collegium Internationale Neuropsychopharmacologicum (CINP)"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1176\/appi.ajp.160.7.1209","article-title":"Relapse prevention in schizophrenia with new-generation antipsychotics: a systematic review and exploratory meta-analysis of randomized, controlled trials","volume":"160","author":"S Leucht","year":"2003","journal-title":"The American journal of psychiatry"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1176\/appi.ajp.2007.06071075","article-title":"Adjunctive treatment with a dopamine partial agonist, aripiprazole, for antipsychotic-induced hyperprolactinemia: a placebo-controlled trial","volume":"164","author":"J-C Shim","year":"2007","journal-title":"American Journal of Psychiatry"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.schres.2008.09.019","article-title":"Effects of aripiprazole on prolactin levels in subjects with schizophrenia during cross-titration with risperidone or olanzapine: analysis of a randomized, open-label study","volume":"107","author":"MJ Byerly","year":"2009","journal-title":"Schizophrenia research"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1124\/jpet.102.033175","article-title":"Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors","volume":"302","author":"KD Burris","year":"2002","journal-title":"The Journal of pharmacology and experimental therapeutics"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"779","DOI":"10.2165\/00023210-200216110-00008","article-title":"Aripiprazole","volume":"16","author":"JK M","year":"2002","journal-title":"Cns Drugs"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/S0014-2999(02)01532-7","article-title":"The antipsychotic aripiprazole is a potent, partial agonist at the human 5-HT1A receptor","volume":"441","author":"S Jordan","year":"2002","journal-title":"European Journal of Pharmacology"},{"key":"ref10","first-page":"235","article-title":"World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects (revised October 7, 2000)","volume":"27","year":"2001","journal-title":"Hiv Clinical Trials"},{"key":"ref11","unstructured":"Segal DL. Diagnostic and statistical manual of mental disorders: DSM-IV-TR: Diagnostic and statistical manual of mental disorders: DSM-IV-TR; 2000."},{"key":"ref12","first-page":"553","article-title":"Pediatric reference values of estradiol, testosterone, lutropin, follitropin and prolactin","volume":"46","author":"N G01ssler","year":"2000","journal-title":"Clinical Laboratory"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1093\/schbul\/13.2.261","article-title":"The positive and negative syndrome scale (PANSS) for schizophrenia","volume":"13","author":"SR Kay","year":"1987","journal-title":"Schizophrenia bulletin"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1177\/0269881103174013","article-title":"The Barnes Akathisia Rating Scale\u2013Revisited","volume":"17","author":"TR Barnes","year":"2003","journal-title":"Journal of Psychopharmacology"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1600-0447.1987.tb10566.x","article-title":"The UKU side effect rating scale: A new comprehensive rating scale for psychotropic drugs and a cross\u2010sectional study of side effects in neuroleptic\u2010treated patients","volume":"76","author":"O Lingjorde","year":"1987","journal-title":"Acta Psychiatrica Scandinavica"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1016\/j.pnpbp.2006.02.001","article-title":"Using aripiprazole to resolve antipsychotic-induced symptomatic hyperprolactinemia: a pilot study","volume":"30","author":"B-H Lee","year":"2006","journal-title":"Progress in Neuro-Psychopharmacology and Biological Psychiatry"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"1978","DOI":"10.1016\/j.pnpbp.2008.09.016","article-title":"Time course of the changes in antipsychotic-induced hyperprolactinemia following the switch to aripiprazole","volume":"32","author":"M-L Lu","year":"2008","journal-title":"Progress in Neuro-Psychopharmacology and Biological Psychiatry"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"e57516","DOI":"10.1371\/journal.pone.0057516","article-title":"Frequency Dependent Alterations in Regional Homogeneity of Baseline Brain Activity in Schizophrenia","volume":"8","author":"R Yu","year":"2013","journal-title":"Plos One"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.4088\/JCP.09m05154yel","article-title":"A multicenter, randomized, double-blind, placebo-controlled, 16-week study of adjunctive aripiprazole for schizophrenia or schizoaffective disorder inadequately treated with quetiapine or risperidone monotherapy","volume":"70","author":"JM Kane","year":"2009","journal-title":"The Journal of clinical psychiatry"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2165\/00023210-200519001-00001","article-title":"Second-generation (atypical) antipsychotics and metabolic effects","volume":"19","author":"JW Newcomer","year":"2005","journal-title":"CNS drugs"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1111\/j.1742-1241.2007.01416.x","article-title":"Metabolic side effects of antipsychotic medication","volume":"61","author":"A Tschoner","year":"2007","journal-title":"International journal of clinical practice"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"514","DOI":"10.4088\/JCP.v69n0401","article-title":"Comorbid somatic illnesses in patients with severe mental disorders: clinical, policy, and research challenges","volume":"69","author":"WW Fleischhacker","year":"2008","journal-title":"Journal of Clinical Psychiatry"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S0920-9964(02)00498-X","article-title":"Obesity as a risk factor for antipsychotic noncompliance","volume":"66","author":"PJ Weiden","year":"2004","journal-title":"Schizophrenia research"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1345\/aph.1G564","article-title":"Naturalistic impact of second-generation antipsychotics on weight gain","volume":"40","author":"DI Brixner","year":"2006","journal-title":"Annals of Pharmacotherapy"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.4088\/JCP.v69n0702","article-title":"A multicenter, randomized, double-blind study of the effects of aripiprazole in overweight subjects with schizophrenia or schizoaffective disorder switched from olanzapine","volume":"69","author":"JW Newcomer","year":"2008","journal-title":"Journal of Clinical Psychiatry"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0139717","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,31]],"date-time":"2019-08-31T09:46:38Z","timestamp":1567244798000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0139717"}},"subtitle":[],"editor":[{"given":"Stephen L","family":"Atkin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2015,10,8]]},"references-count":25,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2015,10,8]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0139717","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,10,8]]}}}